Abciximab
Reopro ® |
| Usual
Diluents |
| NS,
D5W |
| Standard
Dilutions [Amount of drug]
[Infusion volume] [Infusion rate] |
| [9mg (4.5
ml)] [250 ml] [As directed]
|
|
| Stability
/ Miscellaneous |
Indications:
Adjunct to percutaneous transluminal coronary
angioplasty or atherectomy for the prevention of acute
cardiac ischemic complications in patients at high risk
for abrupt closure (restenosis) after treatment.
(Patients at high risk include: acute MI within 12 hours
of onset of symptoms; Non q-wave MI; Early
postinfarction angina or unstable angina with at least 2
episodes of angina associated with EKG changes during
past 24hrs.)
Use as an adjunct with heparin to prevent cardiac
ischemic complications in patients with unstable angina
not responding to conventional treatment when a
percutaneous coronary intervention(PCI) is scheduled
within 24 hours.
Preparation:
Bolus dose: Use 0.22 micron filter to withdraw dose into
syringe. [supplied: 10mg/5 ml vial (REF) ]
Continuous infusion: withdraw 9mg (4.5 ml) through a
0.22 micron filter into a syringe; inject into 250 ml NS
or D5W (35 mcg/ml). Infuse at 17 ml/hr (10 mcg/min) x 12
hours.
Filter all infusions. |
| |
|
|
